Novartis is preparing to make some big changes to its structure following the departure of its operations chief, and a desire to aim for big digital things.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
A life sciences expert has warned that obtaining CRISPR IP rights is expected to become a lot more difficult in the near future.
FDNA has announced a Genomics Collaborative, with the aim of developing new precision medicine approaches that builds on partnerships already underway in the research community.
Google has announced a partnership with WuXi NextCODE, with the aim of enhancing its comprehensive genomics capabilities.
Roche has unveiled plans to place a cancer specialist at the centre of its Swiss-based research efforts in April after the scientist who led the unit for five years, John Reed resigned for personal reasons.
Scott Gottlieb, head of the Food and Drug Administration (FDA) has revealed that a “rigged payment scheme” between drug plans, insurers and pharmaceutical companies has blocked access to less-expensive versions of some of the most expensive drugs in the U.S.
Celgene has entered into a multi-year partnership with biotech firm Vividion Therapeutics, in a bid to accelerate its proteomics and chemistry platforms.
The FDA has announced a plan to modernise its approach to evaluating new drugs for Alzheimer’s and other neurologic diseases.
Designed to accelerate pre-clinical genomic research and drug discovery for the benefit of patients, the team behind the global genomic data marketplace has grown by nearly 50% in the past year.
Helix has successfully closed a $200 million financing round, and has revealed that it plans to expand its personal genomics marketplace to accelerate consumer adoption of genomics.
Shares in Celgene, one of biotech’s most successful companies, has dropped 9% following a drug refusal from the Food and Drug Administration.
AstraZeneca has made the decision to push six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.